Where I see patients (2)
Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.
Journal of geriatric oncology
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Future oncology (London, England)
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Oncology and therapy
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...
The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
Proportion of participants with treatment-emergent adverse events of CAR-T as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, revised cytokine release syndromeCRS grading...
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...
Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lym...
Percent of subjects with adverse events (AEs) with CFT7455 as a single agent